Eli Lilly(AMAM), Crohn’s

Eli Lilly(AMAM), Crohn’s

Title: A Study of Mirikizumab (LY3074828) in Participants With Crohn’s Disease (VIVID-1)

Associated condition: Crohn’s disease

Status: Currently enrolling

Brief summary: This is a Phase 3, multicenter, randomized, double-Blind, placebo- and active- controlled, treat-through study to evaluate the efficacy and safety of mirikizumab in subjects who have moderately to severely active Crohn’s disease. Participants were divided into three study arms: the experimental group received intravenous (IV) and subcutaneous (SC) injections of mirikizumab; the group in the active comparator group received IV and SC injections of ustekinumab; the subjects in the placebo comparator group received placebo IV and SC injections.

Primary objectives: To determine if mirikizumab is safe and effective in participants with moderately to severely active Crohn’s disease.

Estimated length of study: 52 weeks

For more detailed information on this research trial, including eligibility and study design, please visit the clinical trial page at U.S. National Library of Medicine’s website. Note you can submit your information for consideration by submitting the contact form on this page.

Submit Your Information for Consideration

HIPAA COMPLIANT FORM

Title: A Study of Mirikizumab (LY3074828) in Participants With Crohn’s Disease (VIVID-1)

Associated condition: Crohn’s disease

Status: Currently enrolling

Brief summary: This is a Phase 3, multicenter, randomized, double-Blind, placebo- and active- controlled, treat-through study to evaluate the efficacy and safety of mirikizumab in subjects who have moderately to severely active Crohn’s disease. Participants were divided into three study arms: the experimental group received intravenous (IV) and subcutaneous (SC) injections of mirikizumab; the group in the active comparator group received IV and SC injections of ustekinumab; the subjects in the placebo comparator group received placebo IV and SC injections.

Primary objectives: To determine if mirikizumab is safe and effective in participants with moderately to severely active Crohn’s disease.

Estimated length of study: 52 weeks

For more detailed information on this research trial, including eligibility and study design, please visit the clinical trial page at U.S. National Library of Medicine’s website. Note you can submit your information for consideration by submitting the contact form on this page.

Submit Your Information for Consideration